Investigational Drug Information for Ulixertinib
✉ Email this page to a colleague
What is the drug development status for Ulixertinib?
Ulixertinib is an investigational drug.
There have been 11 clinical trials for Ulixertinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Glioma, Neoplasms, and Lymphoma. The leading clinical trial sponsors are BioMed Valley Discoveries, Inc, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are eighteen US patents protecting this investigational drug and two hundred and nine international patents.
Summary for Ulixertinib
| US Patents | 18 |
| International Patents | 209 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 144 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 1 (2018-10-01) |
| Vendors | 40 |
Recent Clinical Trials for Ulixertinib
| Title | Sponsor | Phase |
|---|---|---|
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | BioMed Valley Discoveries, Inc | Phase 1 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Eli Lilly and Company | Phase 1 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | M.D. Anderson Cancer Center | Phase 1 |
Clinical Trial Summary for Ulixertinib
Top disease conditions for Ulixertinib
Top clinical trial sponsors for Ulixertinib
US Patents for Ulixertinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ulixertinib | ⤷ Sign Up | Compounds and compositions as inhibitors of MEK | Novartis AG (Basel, CH) | ⤷ Sign Up |
| Ulixertinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Ulixertinib | ⤷ Sign Up | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Sign Up |
| Ulixertinib | ⤷ Sign Up | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | Loxo Oncology, Inc. (Stamford, CT) Array Biopharma, Inc. (Boulder, CO) | ⤷ Sign Up |
| Ulixertinib | ⤷ Sign Up | Cancer treatment using combinations of ERK and RAF inhibitors | BIOMED VALLEY DISCOVERIES, INC. (Kansas City, MO) | ⤷ Sign Up |
| Ulixertinib | ⤷ Sign Up | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | Karus Therapeutics Limited (Oxfordshire, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ulixertinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ulixertinib | Argentina | AR097326 | 1989-12-31 | ⤷ Sign Up |
| Ulixertinib | Australia | AU2014307593 | 1989-12-31 | ⤷ Sign Up |
| Ulixertinib | Brazil | BR112016001783 | 1989-12-31 | ⤷ Sign Up |
| Ulixertinib | Canada | CA2921300 | 1989-12-31 | ⤷ Sign Up |
| Ulixertinib | Chile | CL2016000150 | 1989-12-31 | ⤷ Sign Up |
| Ulixertinib | China | CN105473588 | 1989-12-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
